Muscle weakness, fatigue and progressive loss of mobility affect the whole family. Could photobiomodulation have a role in muscular dystrophy? We examine specific findings from cells, animal models and an early clinical observation. We also explain how local illumination differs from blood irradiation. Select a question to scroll to its answer within this article.
Which questions will this article answer?
- What is muscular dystrophy, and is it the same as fibromyalgia?
- Why do researchers study light, mitochondria and ATP in dystrophy?
- What did experiments in mice with Duchenne muscular dystrophy show?
- What have newer studies shown about regeneration and cellular maintenance?
- Has PBM been observed in a person with DMD?
- What did the study of laser-irradiated patient blood mean?
- Can illumination over a blood vessel affect a distant muscle?
- Is illuminating a muscle locally the same as ILIB or nasal PBM?
- Can light cure dystrophy or stop its progression?
- Which colour, dose and frequency would be most suitable?
- How should light fit into rehabilitation and specialist care?
- What are the risks, and how should possible benefit be assessed?
Full menu of the light research series — expand
What is muscular dystrophy, and is it the same as fibromyalgia?
Muscular dystrophies are genetic disorders involving progressive muscle damage and weakness. Their course and the organs affected vary. In Duchenne muscular dystrophy (DMD), there is insufficient functional dystrophin, a protein that helps protect muscle fibres. Diagnosis involves specialist assessment and often genetic testing. [1]
Fibromyalgia mainly involves widespread pain, fatigue and sleep difficulties. It is not the same as the genetically driven breakdown of muscle fibres in dystrophy. A pain study in fibromyalgia therefore cannot be presented as evidence of DMD treatment. [2]
Why do researchers study light, mitochondria and ATP in dystrophy?
In DMD, inflammation, oxidative damage and disturbed cellular energy handling accompany the genetic problem. Photobiomodulation investigates whether red or near-infrared light can beneficially influence these associated processes. ATP is a molecule cells use to carry out work, including muscle activity.
Experiments examine cell signalling, mitochondrial condition and regeneration. Favourable changes in these measures do not repair the genetic cause of dystrophy. Altered energy production in a model does not itself demonstrate restored muscle strength in a person. [3][5]
What did experiments in mice with Duchenne muscular dystrophy show?
A 2018 study reported improved muscle function and structure in mdx mice, with dose-dependent findings. This dystrophin-deficient model is used in DMD research. [3]
A 2022 study divided 20 mice into exercise, laser, combined-treatment and control groups. The combination produced favourable findings for strength and some measures of muscle damage. [4]
These are reasons to continue clinical research. However, disease progression and responses to exercise in mice differ from human DMD. The experiment does not provide instructions for more intensive exercise or home light dosing.
What have newer studies shown about regeneration and cellular maintenance?
In 2024, Silva and colleagues studied LED light and idebenone in dystrophic cells and mdx mice. They found changes in autophagy markers and favourable outcomes relating to muscle damage and regeneration. Autophagy is the cellular processing of damaged components; regulation matters, rather than a simple rule that more is better. [5]
Covatti and colleagues studied different stages of dystrophic damage. They observed favourable changes in inflammatory area, macrophage infiltration and oxidative damage in mouse muscle. [6] Neither idebenone nor combinations from an animal experiment are instructions for self-treatment.
Has PBM been observed in a person with DMD?
Yes: a conference case report describes a 15-year-old patient who had previously received gene therapy and was continuing physiotherapy. After adding PBM, the interim assessment at 6 months showed a 12% increase in the NSAA motor-function score. Six-minute walking performance remained stable. The time for the 10 m test increased by 0.7 seconds, so that result was not an improvement. [7][8]
This was one patient without a control group. The APTA and MDA reports describe related observations, not two independent studies. Light cannot be separated from the effects of prior gene therapy, rehabilitation and the natural course of the condition.
What did the study of laser-irradiated patient blood mean?
A 2007 study compared blood from 30 patients with DMD and 20 healthy people. Irradiating collected samples with a helium–neon laser reduced some oxidative-damage markers and altered nitric-oxide measures. [9]
This involved blood outside the body, not clinical laser treatment of patients. It helps investigate a biological response but provides no outcome for walking, muscle strength or slowed dystrophy following nasal or intravenous application.
Can illumination over a blood vessel affect a distant muscle?
Research is investigating this possibility. In 2024, Malavazzi and colleagues studied 85 rats with acute muscle injury. Light delivered through the skin over a tail vessel was associated with favourable repair changes in a distant muscle; timing also influenced the outcome. This was not a muscular dystrophy model. [10]
In a separate experiment in healthy people, PBM combined with a static magnetic field did not produce the same effect when applied to the opposite limb as with local application. [11] Systemic action is therefore a relevant research question, not an automatic property of every protocol.
Is illuminating a muscle locally the same as ILIB or nasal PBM?
No: the route and light dose differ. Local PBM targets muscle through the skin. ILIB delivers light through a fibre inside a vein. Transcutaneous vascular application uses the skin over a vessel, while intranasal application uses the nasal mucosa.
The muscle and blood experiments cited here [3][9][10] do not establish equivalent clinical results for a nasal applicator. This does not prove that intranasal treatment is ineffective; it is a question requiring separate investigation in the specific disease. Home nasal illumination cannot be presented as the same intervention as irradiating mouse muscle or blood outside the body.
Can light cure dystrophy or stop its progression?
The cited studies do not establish a cure or reliable arrest of human DMD. An improved marker in mouse muscle is not evidence of gene repair, and a short-term motor-score improvement does not demonstrate long-term preservation of walking. [3][5][7]
Nor can DMD findings be transferred to Becker, limb-girdle or myotonic dystrophy. [1] Further research should assess added benefit alongside standard care: muscle function, fatigue, everyday activities, quality of life and long-term safety.
Which colour, dose and frequency would be most suitable?
These studies do not provide a validated universal home protocol for muscular dystrophy. Light sources, wavelengths, treatment areas, doses and frequency differ. Colour or a wattage figure alone is insufficient for comparison. [3][4][5][7]
A dose applied to a small mouse muscle cannot be converted simply by human body weight. The same number of minutes does not mean the same dose in the target muscle. The treating team should assess the specific approach; increasing treatment time according to how it feels does not replace a protocol.
How should light fit into rehabilitation and specialist care?
A neuromuscular team and treatment appropriate to the disease type remain central. Exercise in DMD should be individualised, appropriate and include rest; care guidance cautions against excessive loading and intensive eccentric or resistance exercise. Feeling less tired after an application is not a reason to overload muscles. [12]
Medication should not be changed based on a subjective response to light. Heart and breathing assessments remain necessary even when walking or comfort improves. [14] If the team supports complementary PBM use, agree beforehand on the goal, functional monitoring, review date and stopping criteria.
What are the risks, and how should possible benefit be assessed?
Lasers require eye protection and attention to output, instructions and intended use. Inappropriate exposure can damage eyes or skin; the label “cold laser” does not guarantee zero risk. [13] Children, photosensitising medication or damaged skin require individual assessment. Stop application if it causes burning or pain.
With the team, track the same functional tasks, fatigue, tolerance and concurrent treatment changes. A photograph or feeling of warmth does not demonstrate muscle restoration. New or worsening breathlessness, swallowing difficulties or sudden loss of strength require prompt medical assessment. Seek immediate help for severe breathing difficulty. [1][14]
Frequently asked questions – brief answers
What is muscular dystrophy, and is it the same as fibromyalgia?
No. Dystrophy is a genetic disorder damaging muscles; fibromyalgia is a different condition involving mainly widespread pain and fatigue.
Why do researchers study light, mitochondria and ATP in dystrophy?
Research focuses on cellular energy, inflammation and regeneration. PBM is not gene therapy, and an improved laboratory marker alone does not establish clinical benefit.
What did experiments in mice with Duchenne muscular dystrophy show?
Mouse studies reported favourable muscle function and structural findings. We need to establish whether, and under what conditions, these translate to people.
What have newer studies shown about regeneration and cellular maintenance?
Newer experiments support research into cellular maintenance and regeneration. They do not establish that the same combination will restore human muscle.
Has PBM been observed in a person with DMD?
Yes. A case report describes partial improvement and stability in some functions. One patient receiving other treatment is insufficient to confirm PBM efficacy.
What did the study of laser-irradiated patient blood mean?
The study found changes in collected blood after irradiation. It was not a trial of DMD treatment within the patient's body.
Can illumination over a blood vessel affect a distant muscle?
Experiments support investigating distant effects. Their extent and significance depend on the protocol; an acute-injury finding does not prove dystrophy treatment.
Is illuminating a muscle locally the same as ILIB or nasal PBM?
No. Local, intravenous, transcutaneous vascular and nasal applications differ. Findings from one route cannot automatically be transferred to another.
Can light cure dystrophy or stop its progression?
The evidence cited does not establish such an effect in people. The prospect is research into complementary support, not a promise to eliminate a genetic disease.
Which colour, dose and frequency would be most suitable?
No single best colour or universal schedule is established for dystrophy. Animal doses and treatment minutes cannot be transferred directly to home use.
How should light fit into rehabilitation and specialist care?
PBM can only be assessed individually alongside specialist care. It does not replace rehabilitation, medicines or heart and breathing monitoring.
What are the risks, and how should possible benefit be assessed?
Eye protection, correct use and supervision of children matter. Assess function with the team; do not delay care for sudden deterioration or breathing problems while trying light.
Sources and supporting evidence
In-text links lead to the relevant sources. Studies 3–6 are preclinical; 7 and 8 are related conference reports of one case; 9 examines collected blood. Studies 10 and 11 are not trials of dystrophy treatment in people. For sources 3, 4 and 6, we use the available abstracts; the remaining evidence is distinguished in the text. Checked 10 November 2026.
- NINDS. Muscular Dystrophy — overview, diagnosis and care. Open source ↗
- NIAMS. Fibromyalgia: Diagnosis, Treatment, and Steps to Take. Open source ↗
- Albuquerque-Pontes et al. (2018). Photobiomodulation therapy protects skeletal muscle and improves muscular function of mdx mice in a dose-dependent manner through modulation of dystrophin. DOI: 10.1007/s10103-017-2405-5. Open source ↗
- Arıkan et al. (2022). Effects of moderate aerobic exercise, low-level laser therapy, or their combination on muscles pathology, oxidative stress and irisin levels in the mdx mouse model of Duchenne muscular dystrophy. DOI: 10.1007/s10103-022-03562-8. Open source ↗
- Silva et al. (2024). LEDT and Idebenone treatment modulate autophagy and improve regenerative capacity in the dystrophic muscle through an AMPK-pathway. PLOS ONE. DOI: 10.1371/journal.pone.0300006. Open source ↗
- Covatti et al. (2024). Photobiomodulation Therapy Effects at Different Stages of the Dystrophic Phenotype: A Histomorphometric Study. DOI: 10.1016/j.jmpt.2024.09.008. Open source ↗
- Harvey et al. (2024). Clinical application of photobiomodulation in Duchenne muscular dystrophy: an observational case study. APTA Pediatrics conference abstract. Open source ↗
- Harvey et al. Clinical Application of Photobiomodulation in DMD. MDA conference abstract, poster T318; related report of the same case. Open source ↗
- Abdel Salam, Abdel-Meguid, Korraa (2007). Markers of oxidative stress and aging in Duchene muscular dystrophy patients and the possible ameliorating effect of He:Ne laser. Acta Myologica 26(1):14–21. Open source ↗
- Malavazzi et al. (2024). Preventive and therapeutic vascular photobiomodulation decreases the inflammatory markers and enhances the muscle repair process in an animal model. DOI: 10.1016/j.jphotobiol.2024.112921. Open source ↗
- Does photobiomodulation therapy combined to static magnetic field (PBMT-sMF) promote ergogenic effects even when the exercised muscle group is not irradiated? (2020). Randomized, triple-blind, placebo-controlled trial. DOI: 10.1186/s13102-020-00197-6. Open source ↗
- Birnkrant et al. (2018). Diagnosis and management of Duchenne muscular dystrophy, part 1. Lancet Neurology. DOI: 10.1016/S1474-4422(18)30024-3. Open source ↗
- FDA. Frequently Asked Questions About Lasers — eye and skin safety. Open source ↗
- Birnkrant et al. (2018). Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. DOI: 10.1016/S1474-4422(18)30025-5. Open source ↗











